Ridgefield pharma resolves legal impasse for Humira rival
Boehringer Ingelheim Pharmaceuticals announced a resolution of its litigation with AbbVie that had delayed its introduction of a “biosimilar” alternative to the AbbVie blockbuster drug Humira.
Under the agreement, Boehringer Ingelheim will be able to begin selling its Cyltezo alternative to Humira beginning in July 2023.
Boehringer Ingelheim is based in Germany with its U.S. pharmaceutical headquarters in Ridgefield. The settlement is limited to U.S. sales only, with the companies not providing financial terms of their licensing agreement.
Alex.Soule@scni.com; 203-842-2545; @casoulman